ArticleJournal of robotic surgery2025
Reframing robotics in Mohs surgery for rare cutaneous sarcomas: conceptual promise and clinical realities in precision oncology.
Article in Journal of robotic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dermatofibrosarcoma protuberans (DFSP) is a rare, locally aggressive cutaneous sarcoma in which achieving histologically negative margins is paramount to minimizing recurrence. Mohs micrographic surgery (MMS) has transformed margin control in DFSP by enabling sequential, layer-by-layer excision with immediate histologic assessment, yet it remains technically challenging in anatomically complex sites and in cases with ambiguous deep or subclinical peripheral spread. Recent advances in robotic microsurgical platforms-characterized by tremor elimination, high-resolution imaging, and ergonomic interfaces-offer a conceptual framework for enhancing the precision and consistency of MMS. However, existing systems are optimized for deep-tissue procedures and lack the tactile sensitivity, superficial field adaptability, and integration with dermatologic mapping protocols essential for skin-level margin evaluation. Similarly, proposals to incorporate artificial intelligence for real-time histopathologic interpretation encounter significant regulatory, validation, and generalizability hurdles. We contend that while the convergence of robotics and AI with MMS holds promise for the future of dermatologic precision oncology, it remains a conceptual endeavor requiring fundamental reengineering, rigorous clinical validation, and regulatory alignment. We call for interdisciplinary collaboration among dermatologic surgeons, engineers, and pathologists to chart a realistic translational pathway toward surface-level robotic excisions in sarcoma care.
Indexed as
Identifiers
40782288What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.